ATE365554T1 - Methode zur behandlung von erkrankungen der unteren harnwege - Google Patents

Methode zur behandlung von erkrankungen der unteren harnwege

Info

Publication number
ATE365554T1
ATE365554T1 AT04758741T AT04758741T ATE365554T1 AT E365554 T1 ATE365554 T1 AT E365554T1 AT 04758741 T AT04758741 T AT 04758741T AT 04758741 T AT04758741 T AT 04758741T AT E365554 T1 ATE365554 T1 AT E365554T1
Authority
AT
Austria
Prior art keywords
urinary
symptom
sub
subject
urinary tract
Prior art date
Application number
AT04758741T
Other languages
German (de)
English (en)
Inventor
Steven Landau
Cheryl Miller
Matthew Fraser
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE365554T1 publication Critical patent/ATE365554T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT04758741T 2003-04-04 2004-04-02 Methode zur behandlung von erkrankungen der unteren harnwege ATE365554T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46102203P 2003-04-04 2003-04-04
US49650203P 2003-08-20 2003-08-20
US53634104P 2004-01-13 2004-01-13

Publications (1)

Publication Number Publication Date
ATE365554T1 true ATE365554T1 (de) 2007-07-15

Family

ID=33162987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04758741T ATE365554T1 (de) 2003-04-04 2004-04-02 Methode zur behandlung von erkrankungen der unteren harnwege

Country Status (9)

Country Link
US (5) US6846823B2 (https=)
EP (1) EP1539181B1 (https=)
JP (1) JP2006522144A (https=)
AT (1) ATE365554T1 (https=)
AU (1) AU2004227945B2 (https=)
CA (1) CA2519379A1 (https=)
DE (1) DE602004007225T2 (https=)
ES (1) ES2290741T3 (https=)
WO (1) WO2004089288A2 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7085845B2 (en) * 2001-05-09 2006-08-01 Gene Fein Method, apparatus and computer program product for identifying a playing media file and tracking associated user preferences
CN100355419C (zh) * 2002-06-07 2007-12-19 安斯泰来制药有限公司 治疗膀胱过度活动的药物
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
EP1539181B1 (en) * 2003-04-04 2007-06-27 Dynogen Pharmaceuticals Inc. Method of treating lower urinary tract disorders
WO2005011683A1 (ja) * 2003-08-04 2005-02-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
CA2560279A1 (en) * 2004-03-19 2005-09-29 Solvay Pharmaceuticals Gmbh Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
WO2006042679A1 (de) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
WO2006066110A2 (en) * 2004-12-14 2006-06-22 The Johns Hopkins University Cav2 RELATED COMPOSITIONS AND METHODS
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
DK2839830T3 (da) * 2005-01-14 2019-08-19 Urigen Inc Kits og sammensætninger til behandling af lidelser i de nedre urinveje
EP1855680A2 (en) * 2005-02-25 2007-11-21 Solvay Pharmaceuticals, Inc. Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US20070093520A1 (en) * 2005-04-15 2007-04-26 Caras Steven D Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
US20070172507A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
US20070172508A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
EP1997807A1 (en) * 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US20090112197A1 (en) * 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
CA2673545A1 (en) * 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
US20090274722A1 (en) * 2007-01-29 2009-11-05 Ligums John E Therapeutic Composition for the Treatment of BPH and ED
MX2009010000A (es) * 2007-03-19 2010-03-17 Insuline Medical Ltd Dispositivo para el suministro de farmaco.
EP2136863A2 (en) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Device for drug delivery and associated connections thereto
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
AU2008259864C1 (en) * 2007-05-30 2014-03-06 Microdose Therapeutx, Inc. Methods and compositions for administration of Oxybutynin
WO2008157205A2 (en) * 2007-06-15 2008-12-24 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US20110182970A1 (en) * 2007-10-30 2011-07-28 Hyde Roderick A Nitric oxide sensors and systems
US10080823B2 (en) * 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
DK2216021T3 (da) 2007-11-02 2012-11-05 Astellas Pharma Inc Farmaceutisk sammensætning til behandling af overaktiv blære
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
CA2743027C (en) 2008-11-07 2016-04-12 Insuline Medical Ltd. Device and method for drug delivery
WO2010077669A2 (en) * 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
US20110000481A1 (en) * 2009-07-01 2011-01-06 Anand Gumaste Nebulizer for infants and respiratory compromised patients
ES2702753T3 (es) * 2010-01-05 2019-03-05 Microdose Therapeutx Inc Dispositivo de inhalación
WO2018071435A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2020030777A1 (en) * 2018-08-10 2020-02-13 Grünenthal GmbH Composition for treating urinary frequency and/or urinary urgency

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046489A (en) 1958-11-28 1962-07-24 Elcor Inc Wide band direct coupled amplifier
US3161155A (en) 1961-02-04 1964-12-15 Orlandi Giorgio Food-dough cords spacing device
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
DE3422155A1 (de) 1984-06-14 1985-12-19 Alfred Teves Gmbh, 6000 Frankfurt Hydraulische servofahrzeugbremse
IE880255L (en) 1987-01-30 1988-07-30 American Home Prod Des-epidermal growth factor activators.
DE3885357T2 (de) 1987-06-29 1994-03-24 Duphar Int Res Anellierte Indolderivate.
US5225407A (en) 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
CA2044854A1 (en) * 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
WO1993000074A1 (en) 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
JP2699794B2 (ja) 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
DK0855397T3 (da) 1995-07-28 2001-06-25 Dainippon Pharmaceutical Co (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse
AU702594B2 (en) 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
CA2286076C (en) 1997-04-18 2006-12-12 Janssen Pharmaceutica N.V. Use of 5ht3 antagonists for promoting intestinal lavage
JPH10298078A (ja) 1997-05-06 1998-11-10 Mitsubishi Chem Corp 抗不安薬
DE19813661A1 (de) 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
WO2000024716A1 (en) 1998-10-23 2000-05-04 Ajinomoto Co., Inc. Dihydropyridine derivatives and drug compositions containing the same
US6272553B2 (en) * 1998-11-20 2001-08-07 Sprint Communications Company, L.P. Multi-services communications device
ES2327600T3 (es) 1999-02-18 2009-11-02 Novasearch Ag Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas.
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
US6589570B1 (en) * 1999-04-12 2003-07-08 University Of Madras Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
DE19929197A1 (de) 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
US6465458B1 (en) 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US6846496B1 (en) * 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
WO2001051496A1 (en) * 2000-01-14 2001-07-19 Rhodia, Inc. Crosslinking agents for textile finishing baths
PT1257277E (pt) 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
JP2002026134A (ja) * 2000-07-12 2002-01-25 Seiko Epson Corp 半導体集積回路の製造方法及びこの方法により製造した半導体集積回路
GB0112494D0 (en) 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
WO2003061657A1 (en) 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
GB0202265D0 (en) 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
CA2491836C (en) 2002-07-10 2011-01-25 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
AU2003259373B2 (en) 2002-08-29 2006-03-09 Dynogen Pharmaceuticals, Inc. New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine
MXPA05007381A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para el tratamiento de transtornos funcionales del intestino.
NZ541009A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
EP1539181B1 (en) * 2003-04-04 2007-06-27 Dynogen Pharmaceuticals Inc. Method of treating lower urinary tract disorders
US7356884B2 (en) * 2003-12-18 2008-04-15 3M Innovative Properties Company Fastener for a display page

Also Published As

Publication number Publication date
AU2004227945B2 (en) 2006-10-26
CA2519379A1 (en) 2004-10-21
DE602004007225D1 (de) 2007-08-09
US20050282799A1 (en) 2005-12-22
WO2004089288A3 (en) 2005-04-21
AU2004227945A1 (en) 2004-10-21
EP1539181B1 (en) 2007-06-27
DE602004007225T2 (de) 2008-03-06
US20050026909A1 (en) 2005-02-03
US20040209869A1 (en) 2004-10-21
EP1539181A2 (en) 2005-06-15
ES2290741T3 (es) 2008-02-16
US20050272719A1 (en) 2005-12-08
EP1539181A4 (en) 2005-12-28
WO2004089288A2 (en) 2004-10-21
US20050020577A1 (en) 2005-01-27
US7115606B2 (en) 2006-10-03
US6846823B2 (en) 2005-01-25
JP2006522144A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
ATE365554T1 (de) Methode zur behandlung von erkrankungen der unteren harnwege
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
WO2003047558A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
DE69820066D1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
DE50114181D1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
DE69826677D1 (de) Trizyclische vasopressin agoniste
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
SE0301883D0 (sv) New use II
SE0103858D0 (sv) Pharmaceutical composition
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens
SE0301885D0 (sv) New use IV
NZ535199A (en) Use of an inhibitor or antagonist against tissue factor
ATE454153T1 (de) 5-ht4 antagonisten zur behandlung von herzversagen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties